Screener

Deferred revenue, current portion

Name: BridgeBio Pharma Deferred revenue, current portion by Products & Services
Creator: OpenCapital
License: https://www.opencapital.sh/terms

BridgeBio Pharma·Products & Services·1 segment·Rolls up to Deferred Revenue

Breakdown

Segment	Q3 '25	Q4 '25	Q1 '26
Research and Development Services	$900K	$800K	$800K
Total	$9.09M	$7.19M	$6.12M

Segments

Research and Development ServicesView metric